Table 1 Demographic and clinical characteristics of study participants.
Characteristics | No. (%)a, mean ± SD, or range |
|---|---|
Age (years) | |
Mean | 72.5 ± 15.6 |
Range | 26–96 |
< 65 | 3 (15.8) |
≥ 65 | 16 (84.2) |
Gender | |
Male | 14 (73.7) |
Female | 5 (26.3) |
Past medical history | |
DM | 3 (15.8) |
DED | 9 (47.4) |
SS | 2 (10.5) |
Atopic dermatitis | 1 (5.3) |
Anti-glaucoma agents (preservative) | |
Long-term medications | |
Latanoprost (BAK) | 10 (38.5) |
Carteolol (BAK) | 5 (19.2) |
Brimonidine (purite) | 4 (15.4) |
Dorzolamide/Timolol (BAK) | 4 (15.4) |
Timolol (BAK) | 2 (7.7) |
Pilocarpine (BAK) | 1 (3.8) |
Last-added mediations | |
Dorzolamide (BAK) | 2 (33.3) |
Latanoprost (BAK) | 2 (33.3) |
Carteolol (BAK) | 1 (16.7) |
Dorzolamide/Timolol (BAK) | 1 (16.7) |
Durations of anti-glaucoma agents usage | |
Long-term medications | |
≤ 3 months | 4 (18.2) |
> 3 months, ≤ 1 year | 8 (36.4) |
> 1 year, ≤ 5 years | 6 (27.3) |
> 5 years | 4 (18.2) |
Last-added medications | |
≤ 1 month | 3 (50) |
> 1 month | 3 (50) |
Types of pseudodendritic lesions | |
I | 1 (3.2) |
II | 21 (67.7) |
III | 2 (6.5) |
IV | 2 (6.5) |
V | 5 (16.1) |
Locations of pseudodendritic lesions | |
Upper | 0 |
Center | 16 (51.6) |
Lower | 15 (48.4) |
Orientations of linear pseudodendritic lesions (type I and II lesions) | |
Horizontal | 17 (77.3) |
Curvilinear | 5 (22.7) |
